These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 2908756

  • 1. The cost-effectiveness of maintenance therapy for duodenal ulceration with an H2-antagonist.
    Fox N, Morton RE, Jacobs J.
    Aliment Pharmacol Ther; 1988 Aug; 2(4):297-309. PubMed ID: 2908756
    [Abstract] [Full Text] [Related]

  • 2. Decision analysis of histamine H2-receptor antagonist maintenance therapy versus Helicobacter pylori eradication therapy: a randomised controlled trial in patients with continuing pain after duodenal ulcer.
    Tavakoli M, Prach AT, Malek M, Hopwood D, Senior BW, Murray FE.
    Pharmacoeconomics; 1999 Oct; 16(4):355-65. PubMed ID: 10623364
    [Abstract] [Full Text] [Related]

  • 3. A cost analysis of alternative treatments for duodenal ulcer.
    Imperiale TF, Speroff T, Cebul RD, McCullough AJ.
    Ann Intern Med; 1995 Nov 01; 123(9):665-72. PubMed ID: 7574221
    [Abstract] [Full Text] [Related]

  • 4. Decision analysis of Helicobacter pylori eradication therapy using omeprazole with either clarithromycin or amoxicillin.
    Craig AM, Davey P, Malek M, Murray F.
    Pharmacoeconomics; 1996 Jul 01; 10(1):79-92. PubMed ID: 10160472
    [Abstract] [Full Text] [Related]

  • 5. Review of an extensive worldwide study of a new H2-receptor antagonist, famotidine, as compared to ranitidine in the treatment of acute duodenal ulcer.
    Bianchi Porro G, Dicenta C, Cook T, Humphries TJ.
    J Clin Gastroenterol; 1987 Jul 01; 9 Suppl 2():14-8. PubMed ID: 2887613
    [Abstract] [Full Text] [Related]

  • 6. Treatment of acute duodenal ulcers with famotidine and its comparison with other H2 blockers.
    Akhtar MA, Rashid P, Khan MA.
    J Pak Med Assoc; 1990 Jun 01; 40(6):136-7. PubMed ID: 1975277
    [Abstract] [Full Text] [Related]

  • 7. [Famotidine versus placebo in prevention of the recurrence of duodenal ulcer disease. A multicenter study in Germany, Austria and Italy].
    Baglioni A, Barbara L, Bianchi-Porro G, Blasi A, Canelli B, Cheli R, Dal Monte R, Dammann HG, Francavilla A, Hentschel E.
    Z Gastroenterol; 1985 Dec 01; 23(12):665-9. PubMed ID: 2868581
    [Abstract] [Full Text] [Related]

  • 8. Maintenance therapy of duodenal ulcer with famotidine. A multicenter United States study.
    Texter EC, Navab F, Mantell G, Berman R.
    Am J Med; 1986 Oct 24; 81(4B):25-32. PubMed ID: 2877571
    [Abstract] [Full Text] [Related]

  • 9. The histological maturity of regenerating mucosa of healed duodenal ulcer and ulcer recurrence after treatment with H2-antagonist.
    Pan S, Liao CH.
    Am J Gastroenterol; 1990 Aug 24; 85(8):949-52. PubMed ID: 1973870
    [Abstract] [Full Text] [Related]

  • 10. Famotidine in the USA: a review of efficacy studies.
    Gitnick G.
    J Int Med Res; 1989 Aug 24; 17 Suppl 1():17A-24A. PubMed ID: 2566539
    [Abstract] [Full Text] [Related]

  • 11. Switching the histamine H2 receptor antagonist famotidine to nonprescription status in Canada. An economic evaluation.
    Tasch RF, Goeree R, Henke CJ, O'Brien BJ.
    Pharmacoeconomics; 1996 Jan 24; 9(1):61-75. PubMed ID: 10160088
    [Abstract] [Full Text] [Related]

  • 12. [Treatment of duodenal ulcer with famotidine].
    Schütze K, Hentschel E, Reichel W, Kerstan E.
    Wien Med Wochenschr; 1987 Sep 15; 137(17):409-11. PubMed ID: 2891224
    [Abstract] [Full Text] [Related]

  • 13. Famotidine in the treatment of gastric and duodenal ulceration: overview of clinical experience.
    Bianchi Porro G.
    Digestion; 1985 Sep 15; 32 Suppl 1():62-9. PubMed ID: 2866137
    [Abstract] [Full Text] [Related]

  • 14. [Famotidine. Pharmacologic and clinical profile of the new histamine H2 receptor antagonist].
    Müller P, Dammann HG, Simon B.
    Fortschr Med; 1986 Apr 17; 104(15):319-22. PubMed ID: 2872147
    [No Abstract] [Full Text] [Related]

  • 15. Economic and health aspects of peptic ulcer disease and H2-receptor antagonists.
    Jensen DM.
    Am J Med; 1986 Oct 24; 81(4B):42-8. PubMed ID: 2877574
    [Abstract] [Full Text] [Related]

  • 16. [Famotidine (quamatel) for treatment of ulcer disease].
    Bogachev RS, Levina ZK.
    Khirurgiia (Mosk); 1999 Oct 24; (1):34. PubMed ID: 10050509
    [No Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness of treatment regimens for the eradication of Helicobacter pylori in duodenal ulcer.
    Vakil N, Fennerty MB.
    Am J Gastroenterol; 1996 Feb 24; 91(2):239-45. PubMed ID: 8607487
    [Abstract] [Full Text] [Related]

  • 18. The use of H2-receptor antagonist in the treatment of peptic ulcer disease in children.
    Tam PK, Saing H.
    J Pediatr Gastroenterol Nutr; 1989 Jan 24; 8(1):41-6. PubMed ID: 2567346
    [Abstract] [Full Text] [Related]

  • 19. Famotidine versus ranitidine for the short-term treatment of duodenal ulcer.
    Simon B, Dammann HG, Jakob G, Miederer SE, Müller P, Ottenjann R, Paul F, Scholten T, Schütz E, Seifert E.
    Digestion; 1985 Jan 24; 32 Suppl 1():32-7. PubMed ID: 2866134
    [Abstract] [Full Text] [Related]

  • 20. Famotidine (Pepcid).
    Med Lett Drugs Ther; 1987 Feb 13; 29(733):17-8. PubMed ID: 2880282
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.